Breast Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
Select
13073B A Multi-Modality Surveillance Program for Women At High Risk for Breast Cancer
9127 Improved MRi Images of Breast Lesions (not all cancer patients)
15837A A Long Term Investigation of Curative Treatment in Breast Cancer Patients
Select
10-183-B Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial)
11365B Computer-Aided Diagnosis of Breast Lesions in Mammograms
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
12-2052 Improved Management of High Risk Breast Lesions with Quantitative MRI
Select
IRB13-0775 Validation of a Polygenic Neurotoxicity Risk Score in Patients with Unusually Severe Paclitaxel-Induced Neuropathy
Select
IRB13-1000 Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Select
IRB13-1193 A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple- Negative Breast Cancer (The METRIC Study)
Select
IRB13-1337 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Select
IRB13-1365 A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Select
IRB13-1389 Phase I Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast or Ovarian Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0194 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Select
IRB14-0712 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Select
CIRB14-0810 NSABP-B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Select
CIRB14-0811 NRG-BR001: Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Select
IRB14-0424 A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
IRB14-0461 Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
CIRB14-1036 NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Select
IRB14-0930 A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physicians Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
Select
IRB14-0987 A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors
Select
IRB14-1429 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumor
IRB15-0066 Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study
Select
IRB15-0091 An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
Select
CIRB15-0239 NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Select
IRB15-0590 A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
Select
IRB15-0647 Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma in Situ (DCIS)
Select
IRB15-0500 A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC)
Select
IRB15-0591 A Randomized Phase II Study of Adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
IRB15-0826 Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density following Oral Contraceptive Therapy
Select
IRB15-1024 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Select
IRB15-1130 Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team